<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605265</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-R005</org_study_id>
    <nct_id>NCT02605265</nct_id>
  </id_info>
  <brief_title>Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1</brief_title>
  <acronym>CinClare</acronym>
  <official_title>A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluate the addition of Irinotecan in neoadjuvant chemoradiation. Half of
      participants will receive capecitabine alone together with neoadjuvant CRT, followed by a
      cycle of XELOX, while the other will receive capecitabine and irinotecan during CRT, followed
      by a cycle of XELIRI. All participants will be scheduled to receive surgery 6-8 weeks after
      the completion of CRT, then 5 cycles of adjuvant chemotherapy of XELOX.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>Surgery scheduled 6-8 weeks after the end of chemoradiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Control rate</measure>
    <time_frame>From date of randomization until the date of first documented pelvic failure, assessed up to 10 years</time_frame>
    <description>Number of participants with pelvic failure after surgery, evaluated using Kaplan-Meier Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>Surgery scheduled 6-8 weeks after the end of chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent Chemoradiotherapy:
Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week
Chemotherapy in Interval Between CRT and Surgery:
Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1
Surgery:
Scheduled 6-8 weeks after the completion of CRT
Adjuvant Chemotherapy:
Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine with Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent Chemoradiotherapy:
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
Chemotherapy in Interval Between CRT and Surgery:
Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
Surgery:
Scheduled 6-8 weeks after the completion of CRT
Adjuvant Chemotherapy:
Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Pelvic Radiation: 50Gy/25Fx</description>
    <arm_group_label>Capecitabine Alone</arm_group_label>
    <arm_group_label>Capecitabine with Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Capecitabine Alone</arm_group_label>
    <arm_group_label>Capecitabine with Irinotecan</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Capecitabine with Irinotecan</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Capecitabine Alone</arm_group_label>
    <arm_group_label>Capecitabine with Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological confirmed adenocarcinoma

          -  clinical stage T3-4 and/or N+

          -  the distance from anal verge less than 12 cm

          -  without distance metastases

          -  KPS &gt;=70

          -  UGT1A1*28 6/6 or 6/7

          -  without previous anti-cancer therapy

          -  sign the inform consent

        Exclusion Criteria:

          -  pregnancy or breast-feeding women

          -  serious medical illness

          -  baseline blood and biochemical indicators do not meet the following criteria:
             neutrophils≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN

          -  DPD deficiency

          -  UGT1A1*28 7/7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <phone>+86-2164175590</phone>
    <phone_ext>81607</phone_ext>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Zhu, MD</last_name>
      <email>leo.zhu@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Zhu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Chemoradiation</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>UGT1A1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

